BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 30896886)

  • 21. Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
    Ee PL; He X; Ross DD; Beck WT
    Mol Cancer Ther; 2004 Dec; 3(12):1577-83. PubMed ID: 15634651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-302a/b/c/d cooperatively inhibit BCRP expression to increase drug sensitivity in breast cancer cells.
    Wang Y; Zhao L; Xiao Q; Jiang L; He M; Bai X; Ma M; Jiao X; Wei M
    Gynecol Oncol; 2016 Jun; 141(3):592-601. PubMed ID: 26644266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
    Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
    Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs.
    Lv H; He Z; Liu X; Yuan J; Yu Y; Chen Z
    J Cell Biochem; 2007 Sep; 102(1):75-81. PubMed ID: 17372930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
    Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
    Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acyl-CoA synthetase-4 is implicated in drug resistance in breast cancer cell lines involving the regulation of energy-dependent transporter expression.
    Orlando UD; Castillo AF; Medrano MAR; Solano AR; Maloberti PM; Podesta EJ
    Biochem Pharmacol; 2019 Jan; 159():52-63. PubMed ID: 30414939
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.
    Baxter DE; Kim B; Hanby AM; Verghese ET; Sims AH; Hughes TA
    Clin Breast Cancer; 2018 Dec; 18(6):481-488. PubMed ID: 30055962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropilin-1 promotes the oncogenic Tenascin-C/integrin β3 pathway and modulates chemoresistance in breast cancer cells.
    Naik A; Al-Yahyaee A; Abdullah N; Sam JE; Al-Zeheimi N; Yaish MW; Adham SA
    BMC Cancer; 2018 May; 18(1):533. PubMed ID: 29728077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survivin up-regulates the expression of breast cancer resistance protein (BCRP) through attenuating the suppression of p53 on NF-κB expression in MCF-7/5-FU cells.
    Wang QP; Wang Y; Wang XD; Mo XM; Gu J; Lu ZY; Pan ZL; Zhu YX
    Int J Biochem Cell Biol; 2013 Sep; 45(9):2036-44. PubMed ID: 23838170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional Alterations of Multidrug Resistance-Associated Proteins 2 and 5, and Breast Cancer Resistance Protein upon Snail-Induced Epithelial-Mesenchymal Transition in HCC827 Cells.
    Yano K; Todokoro I; Kamioka H; Tomono T; Ogihara T
    Biol Pharm Bull; 2021; 44(1):103-111. PubMed ID: 33390536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiR-548 K regulatory effect on the ABCG2 gene expression in MDR breast cancer cells.
    Saberiyan M; Ghasemi Z; Yaghoobi H
    Cancer Rep (Hoboken); 2023 Jun; 6(6):e1816. PubMed ID: 37166017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene silencing of FANCF potentiates the sensitivity to mitoxantrone through activation of JNK and p38 signal pathways in breast cancer cells.
    Li Y; Zhao L; Sun H; Yu J; Li N; Liang J; Wang Y; He M; Bai X; Yu Z; Zheng Z; Mi X; Wang E; Wei M
    PLoS One; 2012; 7(8):e44254. PubMed ID: 22952942
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.
    Kovalev AA; Tsvetaeva DA; Grudinskaja TV
    Exp Oncol; 2013 Dec; 35(4):287-90. PubMed ID: 24382439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
    Burger H; Foekens JA; Look MP; Meijer-van Gelder ME; Klijn JG; Wiemer EA; Stoter G; Nooter K
    Clin Cancer Res; 2003 Feb; 9(2):827-36. PubMed ID: 12576456
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
    Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
    Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells.
    Zhang W; Feng M; Zheng G; Chen Y; Wang X; Pen B; Yin J; Yu Y; He Z
    Biochem Biophys Res Commun; 2012 Jan; 417(2):679-85. PubMed ID: 22166209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer.
    Asaduzzaman M; Constantinou S; Min H; Gallon J; Lin ML; Singh P; Raguz S; Ali S; Shousha S; Coombes RC; Lam EW; Hu Y; Yagüe E
    Breast Cancer Res Treat; 2017 Jun; 163(3):461-474. PubMed ID: 28341962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.
    Zhang W; Ding W; Chen Y; Feng M; Ouyang Y; Yu Y; He Z
    Acta Biochim Biophys Sin (Shanghai); 2011 Aug; 43(8):647-53. PubMed ID: 21712253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.
    Ilmer M; Mazurek N; Gilcrease MZ; Byrd JC; Woodward WA; Buchholz TA; Acklin K; Ramirez K; Hafley M; Alt E; Vykoukal J; Bresalier RS
    Breast Cancer Res; 2016 Sep; 18(1):97. PubMed ID: 27687248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.